Statera Biopharma Correlations
| STABDelisted Stock | USD 0.04 0.0003 0.82% |
The correlation of Statera Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Statera Biopharma Correlation With Market
Good diversification
The correlation between Statera Biopharma and DJI is -0.04 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Statera Biopharma and DJI in the same portfolio, assuming nothing else is changed.
Statera |
The ability to find closely correlated positions to Statera Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Statera Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Statera Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Statera Biopharma to buy it.
Moving together with Statera Pink Sheet
Moving against Statera Pink Sheet
| 0.71 | ENZN | Enzon Pharmaceuticals | PairCorr |
| 0.61 | CEROW | CERo Therapeutics Symbol Change | PairCorr |
| 0.56 | VAXX | Vaxxinity | PairCorr |
| 0.52 | EPRX | Eupraxia Pharmaceuticals | PairCorr |
| 0.42 | FNCH | Finch Therapeutics | PairCorr |
| 0.41 | EXAI | Exscientia ADR | PairCorr |
| 0.33 | FBIOP | Fortress Biotech Pref | PairCorr |
| 0.48 | NAVB | Navidea Biopharmaceutica | PairCorr |
| 0.36 | ACABU | Atlantic Coastal Acq | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Statera Pink Sheet performing well and Statera Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Statera Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| PKBOW | 17.07 | (4.51) | 0.00 | 5.32 | 0.00 | 32.00 | 130.00 | |||
| NRSNW | 18.17 | 4.55 | 0.13 | (0.72) | 19.74 | 58.82 | 158.33 | |||
| BNOEF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| ATRX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| ELYM | 3.62 | (1.01) | 0.00 | 1.32 | 0.00 | 6.00 | 22.16 | |||
| ACRV | 2.67 | (0.46) | 0.00 | (0.25) | 0.00 | 4.83 | 19.02 | |||
| ALEC | 4.66 | (1.57) | 0.00 | (0.51) | 0.00 | 7.49 | 44.58 | |||
| AADI | 1.91 | 0.31 | 0.12 | 0.36 | 2.17 | 5.08 | 13.95 | |||
| KROS | 3.55 | (1.02) | 0.00 | (0.24) | 0.00 | 6.18 | 82.94 |
View Statera Biopharma Related Equities
| Risk & Return | Correlation |
Statera Biopharma Corporate Management
| George Wagner | Ex Affairs | Profile | |
| Dr Buckheit | Chief Officer | Profile | |
| Christopher Zosh | Interim Fin | Profile | |
| Todd Headley | Exec Devel | Profile | |
| Michael Handley | Pres CEO | Profile |
Still Interested in Statera Biopharma?
Investing in delisted pink sheets can be risky, as the pink sheet is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.